Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 3/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24024526 | 0.83 | TDO2 (0.49) | TDO2GRIN1GRIN2BATMMETAP2 | |
| SCHEMBL20529702 | 0.80 | TDO2 (0.56) | TDO2GRM2 | |
| SCHEMBL24024549 | 0.77 | TDO2 (0.46) | TDO2GRIN1GRIN2BATM | |
| SCHEMBL24024564 | 0.76 | TDO2 (0.53) | TDO2 | |
| SCHEMBL26004908 | 0.75 | TDO2 (0.42) | TDO2ATM | |
| SCHEMBL20529669 | 0.73 | TDO2 (0.51) | TDO2GRM2 | |
| SCHEMBL24024556 | 0.71 | TDO2 (0.47) | TDO2 | |
| SCHEMBL24024584 | 0.69 | TDO2 (0.48) | TDO2 | |
| SCHEMBL20529673 | 0.69 | TDO2 (0.41) | TDO2CYP2C9METAP2GRM2 | |
| SCHEMBL30701769 | 0.69 | TDO2 (0.41) | TDO2CYP2C9METAP2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731966-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2018187480-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731966-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN1B | TDO2 4221/4885GRIN1 141/4885GRIN2B 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.